Skip to main content
OpenTrials
Completed

NCT Number: NCT07605871

Effects of Oral Collagen Drinks on Human Skin

The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Condition Collagen Synthesis Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Ewish Testing Technology Co.,ltd.

Beijing, China

About this study

This study is a single-center, double-blinded, parallel human trial designed to evaluate the skin beauty effect of oral collagen drink and MAXI collagen drink.

Healthy adult participants aged 18-60 years will be enrolled. Participants will be informed to consume test samples daily for 4 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 1 week, and 4 weeks of consumption.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Chinese subjects aged 18 to 60 years, both male and female.
  • Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3.
  • Presence of facial skin laxity and sagging.
  • Ability to undergo skin examinations and pre-treatment in the designated test areas.
  • Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF).

Exclusion criteria

  • Pregnant or lactating women, or those planning to become pregnant in the near future.
  • Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics.
  • Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases.
  • Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair).
  • Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month.
  • Use of cosmetics or other products with similar efficacy within the past 2 weeks.
  • Participation in other human clinical trials for cosmetics within the past month.
  • Any other conditions deemed unsuitable for participation based on clinical assessment.

Treatment and study plan

Collagen Drink

Dietary Supplement

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 5 g Collagen Powder

MAXI Collagen Drink

Dietary Supplement

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 15 mL MAXI Collagen Liquid (equivalent to 5 g of deep hydrolyzed collagen net weight)

MAXI Collagen Drink_High dose

Dietary Supplement

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 30 mL MAXI Collagen Liquid (equivalent to 10 g of deep hydrolyzed collagen net weight)

Primary outcomes

  1. The change of collagen fiber fluorescence intensity

    Time frame: Change from Baseline collagen intensity at 4 weeks

    SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to evaluate the density and quality of dermal collagen fibers.

Secondary outcomes

  1. The change of skin elasticity

    Time frame: Change from Baseline skin elasticity at 4 weeks

    Cutometer® MPA580 (CK, Germany) was utilized to measure the gross elasticity of the skin using suction method.

  2. The change of skin firmness

    Time frame: Change from Baseline skin firmness at 4 weeks

    Cutometer® MPA580 (CK, Germany) was utilized to measure skin firmness and the area under the suction curve.

  3. The change of epidermal thickness

    Time frame: Change from Baseline epidermal thickness at 4 weeks

    SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to measure the depth of the epidermal layer using optical imaging.

  4. The change of cheek skin roughness

    Time frame: Change from Baseline skin roughness at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to measure the arithmetic average roughness (Ra value) of the cheek surface.

  5. The change of the Dermal-Epidermal Junction (DEJ) structures

    Time frame: Change from Baseline DEJ status at 4 weeks

    SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to assess the structural integrity and epithelial-connective tissue interface (ECTI) of the DEJ.

  6. The change of nasolabial folds volume

    Time frame: Change from Baseline wrinkle parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to quantify the 3D morphological changes of the nasolabial folds volume.

  7. The change of nasolabial folds depth

    Time frame: Change from Baseline wrinkle parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to quantify the 3D morphological changes of the nasolabial folds depth.

  8. The change of crow's feet volume

    Time frame: Change from Baseline crow's feet parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to measure the severity of crow's feet volume.

  9. The change of crow's feet depth

    Time frame: Change from Baseline crow's feet parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to measure the severity of crow's feet depth.

  10. The change of the volume of fine lines under the eyes

    Time frame: Change from Baseline fine lines at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to assess the volume of fine lines under the eyes.

  11. The change of the mean depth of fine lines under the eyes

    Time frame: Change from Baseline fine lines at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to assess the mean depth of fine lines under the eyes.

  12. The change of cheek (malar) volume

    Time frame: Change from Baseline cheek volume at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to measure the 3D volume of the cheek area for lifting effects.

  13. The change of jawline length

    Time frame: Change from Baseline jawline parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to measure the linear length and contour of the jawline.

  14. The change of skin pores counts

    Time frame: Change from Baseline pore parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to perform 3D imaging and quantification of skin pores counts.

  15. The change of skin pores volume

    Time frame: Change from Baseline pore parameters at 4 weeks

    AEVA-HE (EOTECH, France) was utilized to perform 3D imaging and quantification of skin pores volume.

  16. The change of skin hydration

    Time frame: Change from Baseline skin hydration at 4 weeks

    Corneometer® CM825 (CK, Germany) was utilized to measure skin surface hydration. Units: arbitrary Corneometer® units 0-120.

  17. The change of transepidermal water loss (TEWL)

    Time frame: Change from Baseline TEWL at 4 weeks

    Tewameter® TM300 (CK, Germany) was utilized to measure the evaporation rate of water from the skin. Units: g/h/m^2.

Other outcomes

  1. The change of skin brightness (L*)

    Time frame: Change from Baseline skin brightness (L*) at 4 weeks

    Skin-Colorimeter CL400 (CK, Germany) was utilized to measure skin brightness (L*).

  2. The change of skin individual typology angle (ITA)

    Time frame: Change from Baseline skin ITA at 4 weeks

    Skin-Colorimeter CL400 (CK, Germany) was utilized to measure skin individual typology angle (ITA).

  3. The change of skin color parameters

    Time frame: Change from Baseline skin redness (a*) at 4 weeks

    Skin-Colorimeter CL400 (CK, Germany) was utilized to measure skin redness (a*).

  4. The change of skin color parameters

    Time frame: Change from Baseline skin yellow tone (b*) at 4 weeks

    Skin-Colorimeter CL400 (CK, Germany) was utilized to measure skin yellow tone (b*).

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 26, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.